Loading…
Loading…
EQUITY / NASDAQ · XNCM
Eupraxia Pharmaceuticals Inc.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →01/01/2025 – 12/31/2025 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗7.24 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 7.24 USD · Volume 1,714,369
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
4 available financial reports
Research reports →SEC FINANCIAL REPORTS
01/01/2025 – 12/31/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Revenue | 0 USD | — | — |
| Net income | -38,576,143 USD | -25,502,536 USD | — |
| Operating cash flow | -28,552,218 USD | -29,994,491 USD | — |
| Cash and cash equivalents | 80,563,482 USD | 33,101,294 USD | +143.38% |
| Total liabilities | 5,703,915 USD | 3,103,386 USD | +83.80% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2024 / Year end01/01/2024 – 12/31/2024ConsolidatedUnits · USD | 2023 / Year end12/31/2023 – 12/31/2023ConsolidatedUnits · USD | 2023 / Year end01/01/2023 – 12/31/2023ConsolidatedUnits · USD |
|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 80,563,482 USD | 33,101,294 USD | — | 19,341,756 USD |
| Financing cash flowCash flow statement | 76,058,540 USD | 45,784,207 USD | — | 21,078,966 USD |
| Investing cash flowCash flow statement | -588,947 USD | -75,159 USD | — | -73,377 USD |
| Net incomeIncome statement | -38,576,143 USD | -25,502,536 USD | — | -28,220,796 USD |
| Operating cash flowCash flow statement | -28,552,218 USD | -29,994,491 USD | — | -20,748,619 USD |
| RevenueIncome statement | 0 USD | — | — | — |
| Total assetsBalance sheet | 86,150,008 USD | 34,942,355 USD | — | 20,266,229 USD |
| Total equityBalance sheet | 82,041,436 USD | 33,404,803 USD | 892,326 USD | 2,216,207 USD |
| Total liabilitiesBalance sheet | 5,703,915 USD | 3,103,386 USD | — | 19,373,903 USD |
| Report source | Open report ↗ Published: 03/13/2026 | Open report ↗ Published: 03/13/2026 | Open report ↗ Published: 03/13/2026 | Open report ↗ Published: 03/20/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.